BRIEF-Beam Therapeutics To Encore Data From Beacon Phase 1/2 Clinical Trial Of Beam-101

Reuters01-23

BRIEF-Beam <a href="https://laohu8.com/S/LENZ">Therapeutics</a> To Encore Data From Beacon Phase 1/2 Clinical Trial Of Beam-101

Jan 23 (Reuters) - Beam Therapeutics Inc BEAM.O:

BEAM THERAPEUTICS TO ENCORE DATA FROM BEACON PHASE 1/2 CLINICAL TRIAL OF BEAM-101 IN SICKLE CELL DISEASE AT 2025 TANDEM MEETINGS OF ASTCT AND CIBMTR

Source text: ID:nGNX1B78fH

Further company coverage: BEAM.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2505509148?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-23 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505509148","market":"us","top_or_hot":-1,"title":"BRIEF-Beam Therapeutics To Encore Data From Beacon Phase 1/2 Clinical Trial Of Beam-101","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Beam <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> To Encore Data From Beacon Phase 1/2 Clinical Trial Of Beam-101</title></head><body><p><span>Jan 23 (Reuters)</span><span> - </span>Beam Therapeutics Inc <span>BEAM.O</span>:</p><ul><li><p>BEAM THERAPEUTICS TO ENCORE DATA FROM BEACON PHASE 1/2 CLINICAL TRIAL OF BEAM-101 IN SICKLE CELL DISEASE AT 2025 TANDEM MEETINGS OF ASTCT AND CIBMTR</p></li></ul><p>Source text: <span>ID:nGNX1B78fH</span></p><p>Further company coverage: <span>BEAM.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Beam Therapeutics To Encore Data From Beacon Phase 1/2 Clinical Trial Of Beam-101</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Beam Therapeutics To Encore Data From Beacon Phase 1/2 Clinical Trial Of Beam-101\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-23 20:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250123:nTUA4RR0LT:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Beam Therapeutics To Encore Data From Beacon Phase 1/2 Clinical Trial Of Beam-101Jan 23 (Reuters) - Beam Therapeutics Inc BEAM.O:BEAM THERAPEUTICS TO ENCORE DATA FROM BEACON PHASE 1/2 CLINICAL ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250123:nTUA4RR0LT:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BEAM","symbol_name":"Beam Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250123:nTUA4RR0LT:1","article_id":"2505509148","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505509148","pubTimestamp":1737633679,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Beam Therapeutics To Encore Data From Beacon Phase 1/2 Clinical Trial Of Beam-101Jan 23 (Reuters) - Beam Therapeutics Inc BEAM.O:BEAM THERAPEUTICS TO ENCORE DATA FROM BEACON PHASE 1/2 CLINICAL T","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BEAM":"Beam Therapeutics, Inc.","BK4588":"碎股","BK4535":"淡马锡持仓","BK4585":"ETF&股票定投概念","BK4556":"基因编辑","BK4505":"高瓴资本持仓","BK4139":"生物科技"},"translate_title":"BRIEF-Beam Therapeutics对BEAM-101 BEACON 1/2期临床试验数据的Encore","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BEAM":0.9},"content_text":"BRIEF-Beam Therapeutics To Encore Data From Beacon Phase 1/2 Clinical Trial Of Beam-101Jan 23 (Reuters) - Beam Therapeutics Inc BEAM.O:BEAM THERAPEUTICS TO ENCORE DATA FROM BEACON PHASE 1/2 CLINICAL TRIAL OF BEAM-101 IN SICKLE CELL DISEASE AT 2025 TANDEM MEETINGS OF ASTCT AND CIBMTRSource text: ID:nGNX1B78fHFurther company coverage: BEAM.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2505509148"}